2-nitro-4-(phenylsulphonyl)aniline | 39070-66-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-nitro-4-(phenylsulphonyl)aniline
• 英文别名: 2-nitro-4-(phenylsulfonyl)aniline；4-benzenesulfonyl-2-nitro-aniline；Phenyl-(3-nitro-4-amino-phenyl)-sulfon；4-Benzolsulfonyl-2-nitro-anilin；2-Nitro-4-phenylsulfon-anilin；4-(benzenesulfonyl)-2-nitroaniline
• CAS: 39070-66-1
• 化学式: C₁₂H₁₀N₂O₄S
• 分子量: 278.288
• InChiKey: MAIPRGSQJOIMIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-nitro-4-(phenylsulphonyl)aniline 在 alkaline solution 、 硫酸 、 溶剂黄146 作用下， 生成 4-hydroxy-3-nitro diphenylsulphone
  参考文献：
  名称：

  48.亚磺酸盐对2：4-二硝基二苯基砜的作用

  摘要：

  DOI：

  10.1039/jr9360000218
• 作为产物：
  描述：

  1-氯-2-硝基-4-(苯基磺酰基)苯 在 甲醇 、 氨 、 水 作用下， 生成 2-nitro-4-(phenylsulphonyl)aniline
  参考文献：
  名称：

  48.亚磺酸盐对2：4-二硝基二苯基砜的作用

  摘要：

  DOI：

  10.1039/jr9360000218

文献信息

• Certain N(4-benzoyl-2-phenyl)-3- trifluoro-2-hydroxy-propanamide
  申请人：Zeneca Limited

  公开号：US05482969A1

  公开（公告）日：1996-01-09

  Compounds of formula I: ##STR1## wherein, ring C, A-B, R.sup.1, n, R.sup.2, and R.sup.3 have any of the meanings given in the specification, and their pharmaceutically acceptable salts are useful in the treatment of urinary incontinence. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

  公式I的化合物：其中，环C，A-B，R.sup.1，n，R.sup.2和R.sup.3具有规范中给定的任何含义，它们的药用盐在治疗尿失禁方面是有用的。还披露了制药组合物，制备公式I化合物和中间体的过程。
• Chemical compounds and their use to elevate pyruvate dehydrogenase activity
  申请人：AstraZeneca AB

  公开号：US06369273B1

  公开（公告）日：2002-04-09

  The use of a compound of the formula (I): wherein: ring C is phenyl or carbon-linked heteroaryl selected from pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl; and wherein said phenyl or heteroaryl is substituted as defined herein; A—B is selected from NHCO, OCH2, SCH2, NHCH2, trans-vinylene, and ethynylene; R1 is linked to ring C at a carbon ortho to the position of A—B attachment and is defined herein; n is 1 or 2; R2 and R3 are alkyl, haloalkyl or together from cycloalkyl or halocycloalkyl as defined herein; in the manufacture of a medicament for use in the elevation of PDH activity in warm-blooded animals such as humans is described. Salts and esters of compounds of formula (I) are also described.

  该化合物的使用公式（I）：其中：环C为苯基或碳链杂环芳基，选择自吡啶基、吡嗪基、嘧啶基和吡啶并吡嗪基；所述苯基或杂环芳基如本文所定义被取代；A—B选择自NHCO、OCH2、SCH2、NHCH2、反式乙烯基和乙炔基；R1与环C连接在与A—B连接位置的邻位碳上，如本文所定义；n为1或2；R2和R3为烷基、卤代烷基或如本文所定义的环烷基或卤代环烷基；描述了制造用于提高温血动物（如人类）PDH活性的药物。还描述了公式（I）化合物的盐和酯。
• 2-fluoroalkyl-1,4-benzoxaxines as potassium channel mediators
  申请人：Zeneca Limited

  公开号：US05486515A1

  公开（公告）日：1996-01-23

  Compounds of formula I ##STR1## wherein X.sup.a, X.sup.b, R, R.sup.1 and R.sup.2 have any of the meanings given in the specification, and their pharmaceutically acceptable salts are useful as potassium channel openers for the treatment of urinary incontinence. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

  式I的化合物##STR1##其中X.sup.a、X.sup.b、R、R.sup.1和R.sup.2具有规范中给定的任何含义，它们的药用盐可用作治疗尿失禁的钾通道开放剂。还披露了制备式I化合物和中间体的药物组合物和工艺。
• 2-hydroxyalkyl-benzimidazoles, -quinazolines and -benzothiazoles as
  申请人：Zeneca Limited

  公开号：US05504089A1

  公开（公告）日：1996-04-02

  Compounds of formula I ##STR1## wherein R.sup.1 -R.sup.4, X, Y, and Z have any of the meanings given in the specification, and their pharmaceutically acceptable salts are useful as potassium channel openers for the treatment of urinary incontinence. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

  公式I的化合物##STR1##其中R.sup.1 -R.sup.4，X，Y和Z具有规范中给出的任何含义，它们的药学上可接受的盐可用于治疗尿失禁的钾通道开放剂。还披露了制备公式I化合物和中间体的制药组合物和过程。
• Therapeutic
  申请人：Zeneca Limited

  公开号：US05900432A1

  公开（公告）日：1999-05-04

  Compounds of formula I: ##STR1## wherein, ring C, A--B, R.sup.1, n, R.sup.2, and R.sup.3 have any of the meanings given in the specification, and their pharmaceutically acceptable salts are useful in the treatment of urinery incontinence. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

  化合物I的式子为：##STR1## 其中，环C，A-B，R.sup.1，n，R.sup.2和R.sup.3具有规范中给出的任何含义，并且它们的药学上可接受的盐在治疗尿失禁方面是有用的。还公开了制药组合物，制备化合物I和中间体的过程。